A carregar...
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC pat...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Medknow Publications
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2721498/ https://ncbi.nlm.nih.gov/pubmed/19675765 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0970-1591.30269 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|